Company: ATRA
Filing Date: 2025-03-31
Form Type: 8-K
Source: 0001193125-25-068789
Chunk: 0

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-31
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On March 25, 2025, it was agreed that the employment of Eric Hyllengren, the Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. (the “ Company”), would end effective March 31, 2025.

In connection with Mr. Hyllengren’s departure from the Company, Mr. Hyllengren is entitled to receive, subject to a general release in favor of the Company, severance benefits under the terms of his employment agreement, which are described in the compensation disclosures of the Company’s Definitive Proxy Statement filed with the SEC on April 26, 2024. Mr. Hyllengren is also entitled to receive his 2024 annual cash bonus at the same time bonuses are paid to eligible employees. In addition, the Company and Mr. Hyllengren entered into a Separation and Consulting Agreement dated March 31, 2025 (the “ Separation and Consulting Agreement”) pursuant to which Mr. Hyllengren will provide consulting services to the Company from March 31, 2025 through July 31, 2025 at an hourly rate. The Separation and Consulting Agreement provides for (i) Mr. Hyllengren to relinquish to the Company all of Mr. Hyllengren’s vested and unvested stock option awards and (ii) the continued vesting during the consulting term of Mr. Hyllengren’s outstanding restricted stock unit awards.

(c)

On March 31, 2025, the Company appointed Yanina Grant-Huerta as the Company’s Chief Accounting Officer and principal accounting officer, effective March 31, 2025.

Ms. Grant-Huerta, age 47, has served as the Company’s Vice President of Financial Planning and Analysis since March 2023. Ms. Grant-Huerta joined the Company in April 2020 as Senior Director of Financial Planning and Analysis. Prior to joining the Company in April 2020, Ms. Grant-Huerta spent 13 years at Amgen Inc. holding roles of increasing responsibility in financial planning and analysis. Yanina Grant-Huerta received her Bachelor’s degree in Economics from Tecnológico de Monterrey and Master’s degree in Statistics from Oklahoma State University.

There are no arrangements or understandings between Ms. Grant-Huerta